THIRD AMENDMENT TO SENIOR ADVISOR AGREEMENTSenior Advisor Agreement • March 15th, 2017 • Opiant Pharmaceuticals, Inc. • Metal mining • California
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • March 15th, 2017 • Opiant Pharmaceuticals, Inc. • Metal mining
This Amendment No. 1 to License Agreement (this “Amendment”) is made as of December 13, 2016, by and among Opiant Pharmaceuticals, Inc. (formerly known as Lightlake Therapeutics Inc.), a Nevada corporation (“Opiant”), and Adapt Pharma Operations Limited, an Irish limited company (“Adapt”). Opiant and Adapt are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined herein have the meanings given to them in the License Agreement (as defined below).
Senior Advisor AgreementSenior Advisor Agreement • March 15th, 2017 • Opiant Pharmaceuticals, Inc. • Metal mining • Nevada
This Agreement is entered into by and between Lightlake Therapeutics Inc. (the “Company”) and Brad Miles (“Miles”) (collectively, the “Parties”) on January 22, 2013 (the “Agreement”).
First Amendment to Senior Advisor AgreementSenior Advisor Agreement • March 15th, 2017 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
This amendment (the “First Amendment”) to the Senior Advisor Agreement by and between Brad Miles (“Miles”) and Lightlake Therapeutics Inc. (the “Company”) dated January 22, 2013 (the “Agreement”) is entered into on February 24, 2015, and hereby amends the terms of the Agreement.
Second Amendment to Senior Advisor AgreementSenior Advisor Agreement • March 15th, 2017 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
This amendment (the “Second Amendment”) to the Senior Advisor Agreement by and between Brad Miles (“Miles”) and Lightlake Therapeutics Inc. (the “Company”) dated January 22, 2013 and amended on February 24, 2015 (collectively, the “Agreement”), is entered into on March 19, 2015, and hereby amends the terms of the Agreement.
ContractPurchase and Sale Agreement • March 15th, 2017 • Opiant Pharmaceuticals, Inc. • Metal mining • New York
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
